Dengue virus serotype 1 pre-membrane protein (DENV-1 prM)

The Dengue virus serotype 1 pre-membrane (prM) protein is a critical structural component of the DENV-1 virion, playing a dual role in viral assembly and maturation. During the assembly of immature virus particles in the endoplasmic reticulum, prM acts as a molecular chaperone for the envelope (E) protein, ensuring its proper folding and preventing its premature acid-triggered fusion within the host cell's secretory pathway (UniProt P17763; PubMed: 11533190). As the immature virion moves through the trans-Golgi network, the host protease furin cleaves prM into the 'pr' peptide and the mature 'M' protein, a transition that is essential for the virus to become infectious (PubMed: 18451165). In the context of disease, prM is a significant target for the immune system; however, antibodies directed against prM are often poorly neutralizing and can contribute to antibody-dependent enhancement (ADE), a phenomenon where sub-neutralizing antibodies facilitate viral entry into Fc-gamma receptor-expressing cells, potentially leading to severe dengue hemorrhagic fever (PubMed: 20448183). Therapeutic strategies involving prM primarily focus on its inclusion in tetravalent vaccines, such as Dengvaxia and Qdenga, to elicit a broad immune response against all four dengue serotypes (PubMed: 26216331).

Other names

Dengue virus type 1 prM proteinPre-membrane proteinprMM protein precursorDENV1 prM

Vaccines and therapeutic antibodies target the prM and E proteins to induce neutralizing antibodies that prevent viral entry or assembly; specifically, prM-targeted antibodies may neutralize the virus or, in some cases, contribute to antibody-dependent enhancement (ADE) by facilitating entry into Fc-receptor-bearing cells.